Zilovertamab
Based on 2 publication(s) in Google Scholar
Zilovertamab (UC-961) is a humanised monoclonal antibody against ROR1 that blocks Wnt5a-induced ROR1 signalling.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity: 98.21%
- CAS No.: 2485779-13-1
- 분자량:145.12 kDa
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications Citing Use of MedChemExpress (MCE) Zilovertamab
More
Biological Activity
제품 설명
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
|
Wnt5A |
In Vitro
Zilovertamab (25 and 50 μg/mL; 72 h) inhibits high-grade serous ovarian cancer (HGSOC) cell proliferation[1].
Zilovertamab (50 μg/mL; 72 h) down-regulates ROR1 expression levels in CaOV3 at the transcriptional level[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:CaOV3, CaOV3CisR, PEO1, and PEO4 cells
-
Concentration:25 and 50 µg/mL
-
Incubation Time:72 hours
-
Result:Reduced the proliferation of CaOV3, CaOV3CisR and PEO1.
-
Cell Line:CaOV3, CaOV3CisR, PEO1, and PEO4 cells
-
Concentration:50 µg/mL
-
Incubation Time:72 hours
-
Result:Down-regulated ROR1 expression levels in CaOV3 at the transcriptional level.
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Gene ID
Accession
Q01973
Target
ROR1
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
신청
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized Human ROR1-ECD-His can bind Zilovertamab. The EC50 for this effect is 3.078 ng/mL.
Chemical Information
-
CAS No. 2485779-13-1
-
Appearance Liquid
-
분자량 145.12 kDa
-
Color Colorless to light yellow
-
SMILES
[Zilovertamab]
-
Synonyms
UC-961; Cirmtuzumab
-
선적
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Mol Ther
Development of a high-affinity anti-ROR1 variable region for broad anti-cancer immunotherapy. [Abstract]2025 Dec 2:S1525-0016(25)00959-1. PMID: 41338184 -
순도&문서
-
Data Sheet (260 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)